Sensititre YeastOne caspofungin susceptibility testing of Candida clinical isolates: correlation with results of NCCLS M27-A2 multicenter study.
The ability of Sensititre YeastOne to discriminate isolates with reduced caspofungin susceptibility was determined against 36 Candida spp. (6 with a known FKS1 mutation). Results were compared with those of M27-A2. The MIC endpoint was 100% growth inhibition. Overall agreement (+/-2 log2) was 87.16%. Sensititre YeastOne detected strains with reduced caspofungin susceptibility.
Cantón
Emilia
E
Unidad de Microbiología Experimental-Centro de Investigación, Hospital Universitario La Fe, Avenida Campanar 21, 46009 Valencia, Spain. canton_emi@gva.es
Pemán
Javier
J
Gobernado
Miguel
M
Alvarez
Elena
E
Baquero
Fernando
F
Cisterna
Ramón
R
Gil
Joaquina
J
Martín-Mazuelos
Estrella
E
Rubio
Carmen
C
Sánchez-Sousa
Aurora
A
Serrano
Carmen
C
D000935:Antifungal Agents / Q000494:pharmacology*; D002175:Candida / Q000145:classification / Q000187:drug effects*; D002177:Candidiasis / Q000382:microbiology; D000077336:Caspofungin; D025141:Drug Resistance, Fungal; D054714:Echinocandins; D006801:Humans; D055666:Lipopeptides; D008826:Microbial Sensitivity Tests / Q000379:methods; D010456:Peptides, Cyclic / Q000494:pharmacology*; D011933:Reagent Kits, Diagnostic
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D010456:Peptides, Cyclic; D011933:Reagent Kits, Diagnostic; D000077336:Caspofungin